Middle East & Africa Colorectal Cancer Treatment Market Size and Forecast (2021

Description

List of Tables

The Middle East & Africa (MEA) colorectal cancer treatment market is projected to grow significantly, reaching an estimated US$ 485.9 million by 2031, up from US$ 408.5 million in 2024, reflecting a compound annual growth rate (CAGR) of 2.5% from 2025 to 2031. This growth is primarily driven by increasing cancer incidence due to factors such as aging populations, urbanization, lifestyle changes, and improvements in healthcare infrastructure across the region.

Countries like the UAE, Saudi Arabia, and South Africa are leading in cancer drug sales, largely due to their advanced healthcare systems and rising cancer rates. The adoption of precision medicine, which includes genetic profiling and biomarker-driven therapies, is becoming more prevalent in oncology practices. Government initiatives and regulatory reforms are facilitating quicker access to innovative oncology drugs, with a focus on promoting biosimilars and generics to enhance affordability.

Strategic collaborations are also playing a crucial role in expanding access to cancer treatments. For instance, Pharmalink's partnership to commercialize sugemalimab across the MEA region is strengthening the precision oncology pipeline. Furthermore, digital health innovations such as telemedicine, AI-driven triage, symptom tracking, and remote consultations are improving access to care, particularly in underserved areas of Sub-Saharan Africa. Platforms like Discovery Health in South Africa and Babylon Health in Kenya are at the forefront of these developments.

Despite these advancements, the region faces significant challenges, particularly in terms of early detection and screening. While some countries, including Saudi Arabia and the UAE, have initiated screening programs, the overall uptake remains low due to public awareness issues, cultural barriers, and limited resources. In Sub-Saharan Africa, the absence of organized screening programs leads to most patients being diagnosed at advanced stages, which severely impacts treatment efficacy and contributes to high mortality rates.

In the Gulf Cooperation Council (GCC) countries, the availability of targeted therapies and immunotherapies is increasing, driven by higher healthcare spending and a focus on specialized cancer centers. Molecular profiling for mutations such as RAS, BRAF, and microsatellite instability-high (MSI-H) is becoming essential for treatment planning. Immunotherapies, particularly immune checkpoint inhibitors, are available in the GCC and are gradually being introduced in select African nations, significantly improving survival outcomes for patients with MSI-H tumors.

The MEA colorectal cancer treatment market is at a pivotal point, facing a rising disease burden exacerbated by demographic and lifestyle changes, alongside substantial gaps in early detection and treatment access. Addressing these challenges through integrated public health strategies, investment in cancer registries and screening programs, and expanding diagnostic and treatment capacities will be crucial for reducing mortality and improving patient outcomes in this diverse region.

While the usage of cancer drugs in the MEA is still modest compared to global standards, the market is on a positive growth trajectory, driven by the increasing cancer burden, demand for precision and immunotherapies, and rising investments in healthcare. However, the success of this growth will depend on overcoming cost, supply chain, and infrastructure challenges to ensure equitable access to treatments across different countries.

The market segmentation reveals that by treatment type, surgery currently dominates the colorectal cancer treatment market, followed by chemotherapy, immunotherapy, targeted therapy, and others. In terms of age demographics, the segment of patients aged 65 and above is the largest, reflecting the higher incidence of colorectal cancer in older populations. Hospitals are the primary end-users of these treatments, indicating a centralized approach to cancer care.

Innovative drug delivery systems are emerging as a transformative trend in colorectal cancer treatment, focusing on precision, reduced systemic toxicity, and enhanced efficacy. Recent advancements include colon-targeted oral nanoparticle systems that encapsulate chemotherapeutics like 5-fluorouracil (5FU) for direct delivery to the colon, significantly improving therapeutic outcomes. Other technologies, such as magnetic nanoparticle-based delivery systems and theranostic nanovectors, are being developed to combine diagnostic imaging with targeted therapy, enhancing treatment precision.

In terms of country-specific insights, the Rest of Middle East & Africa holds the largest market share, with countries like Morocco, Algeria, Nigeria, Egypt, Tunisia, and Libya contributing significantly to the colorectal cancer treatment landscape. Each of these countries faces unique challenges, such as limited healthcare resources and a lack of organized screening programs, which necessitate urgent improvements in cancer care and early detection initiatives.

Key players in the MEA colorectal cancer treatment market include Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Bristol-Myers Squibb Co., among others. These companies are actively pursuing strategies such as product innovation, expansion, and mergers to enhance their market presence and offer cutting-edge treatments to patients.

Product Code: TIPRE00042817

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

5. Middle East & Africa Colorectal Cancer Treatment Market - Key Market Dynamics

5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:

6. Colorectal Cancer Treatment Market - Middle East & Africa Market Analysis

6.1 Middle East & Africa Colorectal Cancer Treatment Market Revenue (US$ Million), 2024 - 2031
6.2 Middle East & Africa Colorectal Cancer Treatment Market Forecast and Analysis

7. Middle East & Africa Colorectal Cancer Treatment Market Revenue Analysis - by Treatment

7.1 Surgery
- 7.1.1 Overview
- 7.1.2 Surgery: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Chemotherapy
- 7.2.1 Overview
- 7.2.2 Chemotherapy: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.3 Immunotherapy
- 7.3.1 Overview
- 7.3.2 Immunotherapy: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.4 Targeted Therapy
- 7.4.1 Overview
- 7.4.2 Targeted Therapy: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

8. Middle East & Africa Colorectal Cancer Treatment Market Revenue Analysis - by Age Group

8.1 Below 49 Years
- 8.1.1 Overview
- 8.1.2 Below 49 Years: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 50 - 64 Years
- 8.2.1 Overview
- 8.2.2 50 - 64 Years: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Above 65 Years
- 8.3.1 Overview
- 8.3.2 Above 65 Years: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

9. Middle East & Africa Colorectal Cancer Treatment Market Revenue Analysis - by End Users

9.1 Hospitals
- 9.1.1 Overview
- 9.1.2 Hospitals: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Specialty Clinics
- 9.2.1 Overview
- 9.2.2 Specialty Clinics: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 Home Care
- 9.3.1 Overview
- 9.3.2 Home Care: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
- 9.4.1 Overview
- 9.4.2 Others: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)

10. Middle East & Africa Colorectal Cancer Treatment Market - Country Analysis

10.1 Middle East & Africa
- 10.1.1 Middle East & Africa Colorectal Cancer Treatment Market Revenue and Forecast and Analysis - by Country
  - 10.1.1.1 Middle East & Africa Colorectal Cancer Treatment Market Revenue and Forecast and Analysis - by Country
  - 10.1.2.2 Saudi Arabia: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
    - 10.1.2.2.1 Saudi Arabia: Middle East & Africa Colorectal Cancer Treatment Market Share - by Treatment
    - 10.1.2.2.2 Saudi Arabia: Middle East & Africa Colorectal Cancer Treatment Market Share - by Age Group
    - 10.1.2.2.3 Saudi Arabia: Middle East & Africa Colorectal Cancer Treatment Market Share - by End Users
  - 10.2.3.3 South Africa: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
    - 10.2.3.3.1 South Africa: Middle East & Africa Colorectal Cancer Treatment Market Share - by Treatment
    - 10.2.3.3.2 South Africa: Middle East & Africa Colorectal Cancer Treatment Market Share - by Age Group
    - 10.2.3.3.3 South Africa: Middle East & Africa Colorectal Cancer Treatment Market Share - by End Users
  - 10.3.4.4 United Arab Emirates: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
    - 10.3.4.4.1 United Arab Emirates: Middle East & Africa Colorectal Cancer Treatment Market Share - by Treatment
    - 10.3.4.4.2 United Arab Emirates: Middle East & Africa Colorectal Cancer Treatment Market Share - by Age Group
    - 10.3.4.4.3 United Arab Emirates: Middle East & Africa Colorectal Cancer Treatment Market Share - by End Users
  - 10.4.5.5 Rest of Middle East & Africa: Middle East & Africa Colorectal Cancer Treatment Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
    - 10.4.5.5.1 Rest of Middle East & Africa: Middle East & Africa Colorectal Cancer Treatment Market Share - by Treatment
    - 10.4.5.5.2 Rest of Middle East & Africa: Middle East & Africa Colorectal Cancer Treatment Market Share - by Age Group
    - 10.4.5.5.3 Rest of Middle East & Africa: Middle East & Africa Colorectal Cancer Treatment Market Share - by End Users

11 Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Positioning & Concentration

12 Industry Landscape

12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments

13 COMPANY PROFILES

13.1 Bayer AG
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Pfizer Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Teva Pharmaceutical Industries Ltd
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Bristol-Myers Squibb Co
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Genentech Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Takeda Pharmaceutical Co Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Amgen Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Regeneron Pharmaceuticals Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Eli Lilly and Co
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Otsuka Holdings Co Ltd
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners